



A proven solution for extended release

Eastman **BIO**SUSTANE™ SAIB NF
pharmaceutical excipient


EASTMAN

Pharmaceutical formulators know that selecting the right excipient is a key decision in the drug development process.

We make that decision easy with Eastman BioSustane™ SAIB NF, a versatile solution that meets the challenges of poor solubility, extended release, depot forming, and abuse deterrence. This innovative excipient has multiple functionalities and is already used in an FDA-approved drug formulation.

BioSustane is a safe, naturally derived product made in a Current Good Manufacturing Practices (CGMP) facility by Eastman, a company known for its high-quality standards.

Chemical structure



BioSustane (sucrose acetate isobutyrate)

R = acetyl, isobutyl, or H

CAS 126-13-6

Product features

BioSustane is sucrose acetate isobutyrate, an esterified sugar derivative with the following attributes:

- Odorless, colorless, viscous liquid
- Viscosity can be greatly reduced with commonly used pharmaceutical solvents.
- Does not crystallize and remains amorphous at ambient temperature
- Nonpolymeric; will not coagulate or precipitate when in contact with aqueous body fluids
- Soluble in organic solvents and dispersible in water with aid of organic solvents and surfactants
- Has bioadhesive and mucoadhesive properties
- Thermally, hydrolytically, and oxidatively stable

Regulatory status

BioSustane SAIB NF is manufactured in a dedicated facility in accordance with CGMP provided for by the International Pharmaceutical Excipient Council. It has a published United States Pharmacopeia National Formulary (USP–NF) monograph and is considered generally recognized as safe (GRAS) by the U.S. FDA. Drug master file 19694 is on file with the FDA.





Marketed products



BioSustane is currently marketed in several formulations, including:

- Posimir—an injectable bupivacaine drug approved by the FDA in February 2021*
- Methydur Sustained Release Capsules—a drug formulation for the treatment of attention-deficit/hyperactivity disorder (ADHD), approved for marketing in Taiwan in September 2018
- SucroMate™—an FDA-approved animal health product

BioSustane enables extended-release formulations.


The highly lipophilic nature of BioSustane makes it an excellent choice for both oral extended-release and injectable depot formulation. Whether administered orally or injected, when exposed to an aqueous environment, BioSustane forms a gel-like matrix depot with the active ingredient trapped inside. The active ingredient is released slowly over time.

Mechanism of extended release of API from BioSustane


Concept: On injection of a solution containing BioSustane, solvent, API, and optional additives, the small amount of solvent diffuses into the surrounding tissue or interstitial fluid and leaves a highly viscous depot from which there is delayed release of the active ingredient. The rate of breakdown of the depot can be slowed through the addition of an additive such as a biodegradable polymer.

Mechanism of release of API from BioSustane depot


API dissolved/dispersed




[Ingestion/
injection]



[Diluent dissipation]



[Drug diffusion]



[Drug diffusion and
BioSustane erosion]



[BioSustane absorption and
final stage of drug release]

Initial drug release

Sustained drug release

The BioSustane advantage for injectables

- Simple formulation—as few as three ingredients
- No complex processing—for example, no microspheres
- Controllable release rate—72 hours to 6 weeks
- Strong solvent and API compatibility

Eastman does not market an injectable grade of BioSustane.

**POSIMIR is a trademark of InnoCell Pharmaceuticals Limited in the U.S. and a trademark of DURECT Corporation outside the U.S.*

BioSustane in FDA-approved injectable drug Posimir

- **Posimir**

Posimir is a bupivacaine solution indicated in adults for administration into the subacromial space under direct arthroscopic visualization to produce postsurgical analgesia for up to 72 hours following arthroscopic subacromial decompression.

- **BioSustane in formulation**

BioSustane acts as a depot-former matrix that provides stable release of bupivacaine for 72 hours.

- **Marketing status**

Posimir is approved for marketing in the U.S. and, subsequently, licensed to Innocoll Biotherapeutics for commercialization.

Possible Posimir formulation

Ingredient	Patent claims	Actual injection solution*
Bupivacaine (free base)	5–20 wt%	132 mg/mL
BioSustane	25–75 wt%	725 mg/mL
Benzyl alcohol	10–55 wt%	220 mg/mL

Local anesthetic for pain control for up to 72 hours

*Maximum bupivacaine dosage = 660 mg, 5 mL solution, single injection

Sources: <https://pdfpiw.uspto.gov/>, Posimir.com, Innocoll.com, FDA, and Eastman research

BioSustane in FDA-approved veterinary drug SucroMate

- **SucroMate**

SucroMate Equine (deslorelin acetate) is a sterile, synthetic gonadotropin-releasing hormone (GnRH) analog suspension. SucroMate Equine is a sustained-release formulation that forms an in situ gel after intramuscular injection.

- **BioSustane in formulation**

BioSustane acts as a depot former that provides a stable release of deslorelin acetate for about 48 hours.

- **Marketing status**

SucroMate is approved for marketing in the U.S.

SucroMate formulation

Ingredient	Amount
Deslorelin acetate	1.8 mg
BioSustane SAIB	700 mg
Propylene carbonate	300 mg

Sources: <https://thornbioscience.com/veterinary-products/>, <https://www.orbit.com/#PatentDocumentPage>



Depots in development

Exploratory ophthalmic formulation with 42-day release

Ingredient	Patent claims	Specific example
Sirolimus	1–5 wt%	3 wt%
BioSustane	0.5–5 wt%	1 wt%
Benzyl benzoate	35–45 wt%	43.6 wt%
Ethanol	3–10 wt%	4.8 wt%
Polyethylene glycol	40–50 wt%	45 wt%
Vitamin E	0.5–2 wt%	1 wt%


Source: U.S. patent 20200383957

Exploratory veterinary formulation with 21-day release


Ingredient	Patent claims	Specific example
Pharma API	Not given	15 wt% (florfenicol)
Triglyceride carrier	5–70 wt%	44 wt% (triacetin)
BioSustane	5–70 wt%	37 wt%
Solvent	30–60 wt%	4 wt% (ethanol)

Source: U.S. patent 20200368263

Extended-release oral formulations demonstrate how the release can be tuned with varying amounts of BioSustane in the formulation.



Extended delivery of pseudoephedrine hydrochloride matrix tablets based on PEO (49.8%–64%) and BioSustane (7.1%–21.3%).



Summary

BioSustane is an excipient with multiple functionalities that help drug formulators find new ways to solve formulation challenges. To learn more about how BioSustane can support your formulation needs or speak with an expert, visit [eastman.com/pharma](https://www.eastman.com/pharma).





Notes

EASTMAN

The results of **insight**[™]

Eastman Corporate Headquarters

P.O. Box 431

Kingsport, TN 37662-5280 U.S.A.

U.S.A. and Canada, 800-EASTMAN (800-327-8626)

Other locations, +(1) 423-229-2000

www.eastman.com/locations

Although the information and recommendations set forth herein are presented in good faith, Eastman Chemical Company ("Eastman") and its subsidiaries make no representations or warranties as to the completeness or accuracy thereof. You must make your own determination of its suitability and completeness for your own use, for the protection of the environment, and for the health and safety of your employees and purchasers of your products. Nothing contained herein is to be construed as a recommendation to use any product, process, equipment, or formulation in conflict with any patent, and we make no representations or warranties, express or implied, that the use thereof will not infringe any patent. NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS OR IMPLIED, OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR OF ANY OTHER NATURE ARE MADE HEREUNDER WITH RESPECT TO INFORMATION OR THE PRODUCT TO WHICH INFORMATION REFERS AND NOTHING HEREIN WAIVES ANY OF THE SELLER'S CONDITIONS OF SALE.

Safety Data Sheets providing safety precautions that should be observed when handling and storing our products are available online or by request. You should obtain and review available material safety information before handling our products. If any materials mentioned are not our products, appropriate industrial hygiene and other safety precautions recommended by their manufacturers should be observed.

© 2022 Eastman. Eastman brands referenced herein are trademarks of Eastman or one of its subsidiaries or are being used under license. The ® symbol denotes registered trademark status in the U.S.; marks may also be registered internationally. Non-Eastman brands referenced herein are trademarks of their respective owners.